Global X Genomics & Biotechnology ETF (GNOM) is a healthcare and biotech ETF. As of October 9, 2026, ETF Copilot scores GNOM 3.6 out of 10 — highest on Growth (7.8), lowest on Quality (0.1). Its ten largest holdings are 55% of the fund.
What stands out in GNOM's data
Global genomics and biotech firms, focused on early-stage innovation.
Earnings margins trail most peers — the fund's bets are on promise, not current profitability.
EBITDA margin of 10.8% lags the category median of 20.5%, though it has improved from its own 7.9% historical median. Top holdings make up 55.2% of assets; the 0.50% fee is typical.
Provides a focused biotech innovation tilt for a portfolio already holding broader health sector exposure.
Why did GNOM move this week? It fell 1.2% in the week to October 9, 2026 — Twist Bioscience and 10X Genomics drove it
GNOM fell 1.2% in the week to October 9, 2026. The holdings that moved it most were Twist Bioscience (−15.3%), 10X Genomics (−13.7%) and Guardant Health (−5.8%); Moderna (+18.4%) pushed the other way.
How is GNOM rated? ETF Copilot scores Global X Genomics & Biotechnology ETF (GNOM) 3.6 out of 10
As of October 9, 2026, ETF Copilot scores Global X Genomics & Biotechnology ETF (GNOM) 3.6 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 3.6 / 10
- Growth: 7.8 / 10
- Risk: 0.5 / 10
- Quality: 0.1 / 10
- Return: 3.9 / 10
What's inside GNOM?
What's inside GNOM: Size (Large 32%, Mid 46%, Small 22%); Geography (International 15%, US 85%); Tech 0.3%; AI 3.3%.
What are GNOM's top holdings? The ten largest are 55% of the fund
Moderna, Twist Bioscience, 10X Genomics, Illumina, Natera, Guardant Health, Genscript Biotech, Bio-Techne, Vertex Pharmaceuticals and Qiagen are GNOM's largest holdings, in that order.
More concentrated than 67% of Health & Biotech ETFs.
Half of GNOM's weight sits in its 9 largest positions, and once those weights are taken into account it behaves like 24 equally weighted holdings.
What is GNOM's expense ratio? 0.50% a year
As of October 9, 2026, GNOM charges 0.50% a year, yields 0.94% and holds $98M in assets across 50 positions.
| Measure | GNOM |
|---|---|
| Expense ratio | 0.50% |
| Dividend yield | 0.94% |
| Assets under management | $98M |
| Holdings | 50 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
Cite this
ETF Copilot, “Global X Genomics & Biotechnology ETF (GNOM) scores and holdings analysis”, as of October 9, 2026.
https://etf-copilot.com/etf/gnom
ETF Copilot Pro unlocks GNOM's price and what each holding weighs.
Try Pro free →